N-homocysteinylated Huntingtin in Huntington's Disease
Status: Not yet recruiting
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin) human control cell lines, unmutated Huntingtin
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:
• Patient with the symptomatic or presymptomatic Huntington's disease gene (CAG >= 36)
• Molecularly confirmed Huntington's disease
• Patient 18 years of age and older
• Person affiliated to or benefiting from a social security assurance
Contact Information
Primary
Mathilde Renaud, MD, PhD
m.renaud2@chru-nancy.fr
03 83 15 36 22
Backup
Nathalie Keil
n.keil@chru-nancy.fr
03 83 15 52 79
Time Frame
Start Date: April 1, 2022
Estimated Completion Date: May 1, 2023
Participants
Target number of participants: 32
Treatments
Experimental: presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin)
Experimental: symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
symptomatic HD individuals with motor UHDRS > 5 (Mutated Huntingtin)
Experimental: human control cell lines, Unmutated Huntingtin
human control cell lines, Unmutated Huntingtin
Authors
Related Therapeutic Areas
Sponsors
Leads: Central Hospital, Nancy, France